Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pan-tumor × Bevacizumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 104 Carcinoma, Hepatocellular 59 Ovarian Neoplasms 56 Carcinoma, Non-Small-Cell Lung 36 Neoplasms 31 Fallopian Tube Neoplasms 25 Colonic Neoplasms 21 Endometrial Neoplasms 19 Breast Neoplasms 19 Brain Neoplasms 18 Glioblastoma 15 Uterine Cervical Neoplasms 14 Stomach Neoplasms 14 Neoplasm Metastasis 14 Rectal Neoplasms 13 Lung Neoplasms 12 Liver Neoplasms 11 Triple Negative Breast Neoplasms 10 Melanoma 10 Colorectal Cancer Metastatic 8 Carcinoma, Renal Cell 8 Recurrence 7 Carcinoma, Ovarian Epithelial 7 Advanced Solid Tumors 7 Squamous Cell Carcinoma of Head and Neck 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Biliary Tract Neoplasms 6 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Gastrointestinal Neoplasms 5

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡